NASDAQ:HIND Vyome (HIND) Stock Price, News & Analysis $2.01 +0.06 (+3.08%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$1.89 -0.12 (-5.97%) As of 04:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings About Vyome Stock (NASDAQ:HIND) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vyome alerts:Sign Up Key Stats Today's Range$1.95▼$2.0150-Day Range$1.93▼$2.3252-Week Range$1.75▼$6.56Volume5,350 shsAverage Volume20,262 shsMarket Capitalization$14.11 millionP/E RatioN/ADividend YieldN/APrice Target$9.25Consensus RatingModerate Buy Company Overview Vyome Holdings, Inc. is a biotechnology company focused on developing therapies for dermatological conditions. The company’s research programs target inflammatory and infectious skin diseases, including acne and other conditions associated with imbalanced skin microbiomes. Vyome has developed topical drug candidates and proprietary approaches intended to selectively address disease-causing bacteria while preserving beneficial microorganisms on the skin. Its pipeline has included investigational treatments for acne and other dermatology indications, although product candidates remain subject to clinical development and regulatory review. The company’s operations are centered on the development of prescription dermatology medicines for potential commercialization in the United States and other international markets. Vyome’s programs are in development, and the availability of approved products may vary by jurisdiction.AI Generated. May Contain Errors. Read More Vyome Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreHIND MarketRank™: Vyome scored higher than 49% of companies evaluated by MarketBeat, and ranked 502nd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingVyome has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialVyome has a consensus price target of $9.25, representing about 360.2% upside from its current price of $2.01.Amount of Analyst CoverageVyome has only been the subject of 2 research reports in the past 90 days.Read more about Vyome's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Vyome is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vyome is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVyome has a P/B Ratio of 3.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.40% of the float of Vyome has been sold short.Short Interest Ratio / Days to CoverVyome has a short interest ratio ("days to cover") of 2.37, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vyome has recently decreased by 22.34%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVyome does not currently pay a dividend.Dividend GrowthVyome does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Vyome this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Vyome to their MarketBeat watchlist in the last 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vyome insiders have not sold or bought any company stock.Percentage Held by Insiders33.00% of the stock of Vyome is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions22.06% of the stock of Vyome is held by institutions.Read more about Vyome's insider trading history. Receive HIND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vyome and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HIND Stock News HeadlinesAverage price target for Vyome Holdings decreased by 23.19% to $9.01September 17, 2026 | msn.comVyome Holdings, Inc. (NASDAQ:HIND) Receives Consensus Rating of "Moderate Buy" from BrokeragesSeptember 15, 2026 | americanbankingnews.comHas Dylan Jovine lost his mind?SpaceX just signed a deal JPMorgan says could unlock the next phase of the space economy, putting the company on a path toward a 10 trillion valuation. But analyst Dylan Jovine says the biggest winner won't be SpaceX itself. He's identified a small firm, less than half a percent SpaceX's size, that partnered with it directly. An upcoming NASA announcement could be the catalyst. Jovine previously flagged Rocket Lab before it climbed from under 4 dollars to over 151. | Behind the Markets (Ad)Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial OfficerSeptember 14, 2026 | finance.yahoo.comVyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial OfficerSeptember 14, 2026 | businesswire.comChardan Capital initiates coverage of Vyome Holdings (HIND) with buy ratingSeptember 4, 2026 | msn.comVyome Holdings Appoints Consulting CFO Jerry LeonardAugust 28, 2026 | tipranks.comVyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance SheetAugust 25, 2026 | finance.yahoo.comSee More Headlines HIND Stock Analysis - Frequently Asked Questions How have HIND shares performed this year? Vyome's stock was trading at $3.44 on January 1st, 2026. Since then, HIND shares have decreased by 41.6% and is now trading at $2.01. How were Vyome's earnings last quarter? Vyome Holdings, Inc. (NASDAQ:HIND) released its earnings results on Wednesday, August, 12th. The company reported ($0.10) EPS for the quarter. The firm had revenue of $0.27 million for the quarter. Vyome had a negative trailing twelve-month return on equity of 197.33% and a negative net margin of 3,024.84%. How do I buy shares of Vyome? Shares of HIND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/12/2026Today9/23/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (12m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 HIND's financial health is in the Yellow zone, according to TradeSmith. HIND has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:HIND CIK1427570 Webvyometx.com Phone(949) 429-6680FaxN/AEmployees18Year FoundedN/APrice Target and Rating Average Price Target for Vyome$9.25 High Price Target$15.00 Low Price Target$3.50 Potential Upside/Downside+360.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($3.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.26 million Net Margins-3,024.84% Pretax Margin-3,097.87% Return on Equity-197.33% Return on Assets-138.14% Debt Debt-to-Equity RatioN/A Current Ratio4.37 Quick Ratio4.37 Sales & Book Value Annual Sales$320 thousand Price / Sales44.09 Cash FlowN/A Price / Cash FlowN/A Book Value$0.67 per share Price / Book3.00Miscellaneous Outstanding Shares7,020,000Free Float4,702,000Market Cap$14.11 million OptionableN/A Beta1.50 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:HIND) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredMy next big call (under $1)While the Senate was failing to pass the CLARITY Act, the SEC already had its own crypto framework on the tabl...Crypto 101 Media | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vyome Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vyome With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
